R&D expense · 2011–2025
Iovance Biotherapeutics R&D expense
$300M+8.7% · FY2025
Iovance Biotherapeutics (IOVA) reported $300M in R&D expense for fiscal 2025, +8.7% year on year.
| Fiscal year | R&D expense | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $300M | +8.7% | Open → |
| FY20242024-12-31 | $276M | −17.1% | Open → |
| FY20232023-12-31 | $333M | +13.0% | Open → |
| FY20222022-12-31 | $295M | +13.8% | Open → |
| FY20212021-12-31 | $259M | +28.4% | Open → |
| FY20202020-12-31 | $202M | +21.5% | Open → |
| FY20192019-12-31 | $166M | +66.3% | Open → |
| FY20182018-12-31 | $99.8M | +39.4% | Open → |
| FY20172017-12-31 | $71.6M | +165.8% | Open → |
| FY20162016-12-31 | $26.9M | +74.1% | Open → |
| FY20152015-12-31 | $15.5M | +301.9% | Open → |
| FY20142014-12-31 | $3.8M | +78.7% | Open → |
| FY20132013-12-31 | $2.2M | +30.1% | Open → |
| FY20122012-12-31 | $1.7M | −5.7% | Open → |
| FY20112011-12-31 | $1.8M | — | Open → |
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2011–2025 compound annual growth +44.4%
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Iovance Biotherapeutics R&D expense |url=https://companiesranked.com/en/company/iovance-biotherapeutics/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Iovance Biotherapeutics R&D expense. CompaniesRanked. https://companiesranked.com/en/company/iovance-biotherapeutics/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-iovance-biotherapeutics-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Iovance Biotherapeutics R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/iovance-biotherapeutics/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001104659-26-018899 · February 24, 2026
{{cite web |title=Iovance Biotherapeutics R&D expense — 10-K (0001104659-26-018899) |url=https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.